

REMARKS/ARGUMENTS

After entry of the amendment, claims 1-7 and 31-52 remain pending. Claims 1, 5 and 6 have been amended. Claims 2-4 and 7 have been withdrawn. Claims 8-30 have been canceled. Claims 31-52 have been added. Applicants reserve the right to pursue such claims in a continuation or divisional application.

Sequence Listing


Applicants believe that the preliminary amendment submitted on October 28, 2003 amended the specification to provide sequence identifiers for each nucleotide and amino acid sequence in the specification. Each sequence is believed to be listed in the paper and computer readable copy of the sequence listing, which were submitted with the preliminary amendment. Specifically, in response to the Examiner's inquiry regarding page 12 of the specification, page 5 of the preliminary amendment provides sequence identifiers for the sequences found on page 12.

Restriction Requirement

The Examiner has restricted prosecution of this application to one of fifteen groups of claims. Applicants elect Group I (claims 1, 5 and 6) without traverse. The pending claims have been amended to recite biological reagents capable of inhibiting transplant rejection, as it reads on the CTLA-4 protein.

The Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,


Stephanie D. Adams, Ph.D.
Patent Agent
Reg. No. 47,378
Tel.: (404) 572-4600
Fax: (404) 572-5145

Date: April 12, 2005
KING & SPALDING LLP
191 Peachtree Street, 45th Floor
Atlanta, Georgia 30303-1763